F16 : Histoplasmose multifocale à Histoplasma capsulatum var duboisii chez un Sénégalais de 22 ans sans immunodépression prouvée

Epidemiology of toxidermia in Dakar: Study of 200 cases

“…L'histoplasmose à Hcd reste rare dans la pratique médicale quotidienne en zone subsaharienne. Des cas isolés sont le plus souvent rapportés souvent chez des patients séronégatif au VIH [1][2][3]. Dans la littérature, l'histoplasmose africaine semble exceptionnelle chez les patients infectés par le VIH [4].…”

The evidence for unavailability of systemic antifungals in Senegal

“…36 These superficial and subcutaneous FDs generally have an arsenal of antifungals that permit their management even if the latter treatment sometimes remains probabilistic. 37 For DFDs, the reported publications essentially concern histoplasmosis, 38,39 especially the African form often treated with disappointment, 15 and cryptococcosis with which alternative treatment regimens have been adopted with a success rate estimated at 36.7%. 40 Rare cases of pneumocystosis 41 and aspergillosis/aspergilloma have been reported, treated by surgery without any adjunction of antifungal for the aspergilloses’ management, possibly due to antifungals unavailability.…”

“…Common Superficial Tinea capitis Ndiaye et al, 16 Kane et al, 17 Ndiaye et al 18 Onychomycoses Seck et al, 19 Sylla et al, 20 Diongue et al 21 Intertrigos Diongue et al, 22 Ndiaye et al, 23 Diongue et al 24 Pityriasis versicolor, otitis and vulvovaginal candidiasis Dioussé et al, 25 Diongue et al, 26 Dieng et al, 27 Sylla et al 28 Subcutaneous Mycetomas Ndiaye et al, 32 Dieng et al, 33 Sow et al, 34 Badiane et al, 35 Diatta et al 37 Deep Cryptococcosis Sow et al, 40 Diallo Mbaye et al, 45 Manga et al 46 Pneumocystosis Dieng et al 41 Uncommon Superficial keratitis, endodontic candidiasis Ndoye et al, 29 Diongue et al, 30 Ndiaye et al 31 Subcutaneous Chromomycosis Develoux et al 36 Deep Histoplasmosis Ndiaye et al, 14 Diadie et al, 15 Diongue et al, 38 Dieng et al 39 Aspergillosis Ndiaye et al, 42 Ade et al, 43 Ba et al 44 Therapeutic Advances in Infectious Disease 8 4 journals.sagepub.com/home/tai…”

“…If the current antifungal arsenal in Senegal has molecules efficient for treating superficial FDs with molecules such as griseofulvin or fluconazole, 13 many deep fungal diseases (DFDs) do not yet benefit from effective treatment with the absence or unavailability of antifungal drugs. 14,15 Consequently, based on data from Aristide Le Dantec and Fann University Hospital Centers in Dakar, which are the only public health establishments with a medical mycology laboratory, the objective of this communication was to update the table of the main FDs diagnosed in Senegal and the antifungals available for their therapeutic management to draw attention to these infections increasingly diagnosed with the emergence of new opportunistic fungi.…”